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Abstract 
Background: Schistosomiasis, caused by infection with blood fluke 
schistosomes, is a neglected tropical disease of considerable 
importance in resource-poor communities throughout the developing 
world. In the absence of an immunoprophylactic vaccine and due to 
over-reliance on a single chemotherapy (praziquantel), 
schistosomiasis control is at risk should drug insensitive schistosomes 
develop. In this context, application of in silico virtual screening on 
validated schistosome targets has proven successful in the 
identification of novel small molecules with anti-schistosomal activity.   
Methods: Focusing on the Schistosoma mansoni histone methylation 
machinery, we herein have used RNA interference (RNAi), ELISA-
mediated detection of H3K4 methylation, homology modelling and in 
silico virtual screening to identify a small collection of small molecules 
for anti-schistosomal testing. A combination of low to high-
throughput whole organism assays were subsequently used to assess 
these compounds’ activities on miracidia to sporocyst transformation, 
schistosomula phenotype/motility metrics and adult worm 
motility/oviposition readouts. 
Results: RNAi-mediated knockdown of smp_138030/smmll-1 (encoding 
a histone methyltransferase, HMT) in adult worms (~60%) reduced 
parasite motility and egg production. Moreover, in silico docking of 
compounds into Smp_138030/SmMLL-1’s homology model 
highlighted competitive substrate pocket inhibitors, some of which 
demonstrated significant activity on miracidia, schistosomula and 
adult worm lifecycle stages together with variable effects on HepG2 
cells. Particularly, the effect of compounds containing a 6-(piperazin-1-
yl)-1,3,5-triazine core on adult schistosomes recapitulated the results 
of the smp_138030/smmll-1 RNAi screens. 
Conclusions: The biological data and the structure-activity 
relationship presented in this study define the 6-(piperazin-1-yl)-1,3,5-
Open Peer Review
Reviewer Status    
Invited Reviewers
1 2 3
version 2
(revision)
13 Nov 2020
report report
version 1
17 Jul 2020 report report report
Adriana Erica Miele , University of Lyon, 
Lyon, France 
Sapienza University of Rome, Rome, Italy
1. 
David Williams , Rush University Medical 
Center, Chicago, USA
2. 
Giovina Ruberti , National Research 
Council, Institute of Biochemistry and Cell 
Biology, Rome, Italy
3. 
Any reports and responses or comments on the 
article can be found at the end of the article.
 
Page 1 of 37
Wellcome Open Research 2020, 5:169 Last updated: 24 NOV 2020
Corresponding author: Gilda Padalino (gip7@aber.ac.uk)
Author roles: Padalino G: Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft 
Preparation, Writing – Review & Editing; Chalmers IW: Resources, Supervision, Writing – Review & Editing; Brancale A: Funding 
Acquisition, Resources, Supervision, Writing – Review & Editing; Hoffmann KF: Conceptualization, Funding Acquisition, Project 
Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing
Competing interests: No competing interests were disclosed.
Grant information: This work was supported by the Wellcome Trust [107475; to KFH]. 
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2020 Padalino G et al. This is an open access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Padalino G, Chalmers IW, Brancale A and Hoffmann KF. Identification of 6-(piperazin-1-yl)-1,3,5-triazine as a 
chemical scaffold with broad anti-schistosomal activities [version 2; peer review: 2 approved, 1 approved with reservations] 
Wellcome Open Research 2020, 5:169 https://doi.org/10.12688/wellcomeopenres.16069.2
First published: 17 Jul 2020, 5:169 https://doi.org/10.12688/wellcomeopenres.16069.1 
triazine core as a promising starting point in ongoing efforts to 
develop new urgently needed schistosomicides.
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Introduction
Schistosomiasis is a parasitic disease caused by a blood fluke 
trematode belonging to the genus Schistosoma. The estimated 
Disability-Adjusted Life Years (DALYs)1 lost for schistosomia-
sis is 25–28 million and it ranks second only to malaria in 
terms of public and economic health importance attributable to a 
human parasitic disease in endemic countries2.
In a scenario where schistosomiasis remains a major cause 
of morbidity and mortality within developing countries2, the 
sustainable use of praziquantel as the only currently licensed 
drug to treat this neglected tropical disease (NTD) remains 
vulnerable3,4. Therefore, there is an urgent need to identify 
novel drugs as an alternative or combinatorial treatment for 
this disease.
In the search for new anti-schistosomal entities, we and others 
have chosen to investigate epigenetic processes due to their 
role in regulating critical aspects of the schistosome life cycle. 
For example, both cytosine methylation and histone acetyla-
tion have previously been shown to control facets of parasite 
motility, fecundity, developmental progression and survival5–8. 
With the Structural Genomics Consortium (SGC)9 making a col-
lection of epigenetic probes/epigenetic inhibitors available for 
research on NTD-causing pathogens, other histone modify-
ing enzyme (HME) machinery components have recently been 
identified as new anti-schistosomal targets10. Amongst the SGC 
collection tested by our laboratory, compounds targeting histone 
methylation regulators (GSK484, GSK-J4, A-196, MS023, 
LLY-507, BAY-598, GSK343 and UNC1999) demonstrated 
potent activities on both schistosomula and adult schistosomes10.
When considering currently known post-translational modifica-
tions of histones, methylation is the second most abundant after 
acetylation11,12. This epigenetic mark is responsible for chromatin 
remodelling and subsequent transcription factor accessibility, 
because methylation alters the interactions between adjacent 
nucleosomes and the arrangement of the double stranded DNA 
wrapped around them11,13. The HMEs involved in this process use 
the cofactor S-adenosyl-methionine (SAM) to transfer a methyl 
group to the side chains of specific amino acids on the histone 
tails (lysine or arginine residues according to the specificity of 
the histone methyltransferases - HMTs)14. This epigenetic mark 
is removed by another class of epigenetic enzyme called the 
histone demethylases (HDMs)15. Recent studies suggest that 
histone methylation plays a crucial role in specific human physi-
ological conditions (including cell-cycle regulation, DNA 
damage and stress response, development and differentiation16–18) 
and alterations of this process appear involved in numerous dis-
eases including cancer, cognitive disorders and ageing19,20. 
However, research focused around histone methylation com-
ponents in schistosomes is currently still young with only a 
few investigations to date suggesting that histone methyla-
tion changes are required for life cycle progression21–25; conse-
quently, schistosome histone methylation machinery components 
represent emerging new drug targets26–28.
Previous studies conducted by our research group, as well as 
others, have explored the druggability of S. mansoni lysine 
specific demethylase 1 (SmLSD1, Smp_150560), a HDM 
involved in parasite fecundity and motility10,28,29. In the current 
study, we specifically investigated the S. mansoni HMT mixed 
lineage leukemia-1 (SmMLL-1; Smp_138030) homologue as a 
potential drug target28. As MLL homologues are essential for 
Caenorhabditis elegans in germline stem cell maintenance and 
fertility30, Drosophila melanogaster development31 and Homo 
sapiens haematopoiesis32, developing a drug discovery pipeline 
centred around SmMLL-1 was rational and additionally 
well-supported by this schistosome protein’s inclusion in 
the TDR Drug Target Database33.
Using a combination of functional genomics and structure-based 
virtual screening (SBVS) methodologies to guide the iterative 
selection of compounds for entering whole-organism assays, 
we present evidence that SmMLL-1 is essential to schistosomula 
survival, adult worm movement, adult worm egg production and 
miracidia to sporocyst transformation. We additionally demon-
strate that the putative SmMLL-1 inhibitors, identified herein, 
all contain a 1,3,5-triazine core linked to a piperazine ring. 
As this chemical scaffold has not previously been associated 
with anti-schistosomal activity, its further medicinal chemistry 
optimisation could lead to the development of a new class 
of urgently-needed anthelmintic.
Methods
Ethics statement
All procedures performed on mice adhered to the United 
Kingdom Home Office Animals (Scientific Procedures) Act 
of 1986 (project license P3B8C46FD) as well as the European 
Union Animals Directive 2010/63/EU and were approved by 
Aberystwyth University’s Animal Welfare and Ethical Review 
Body (AWERB). All animals in this investigation were under 
the care of a Named Animal Care and Welfare Officer (NACWO), 
a Named Veterinary Surgeon (NVS), a small animal techni-
cian, a personal license holder (PIL) and a project license holder 
(PPL). While the procedure performed on these mice (infec-
tion with S. mansoni parasites) is classified within the moderate 
severity band of our license, efforts to ameliorate harm (outside 
of that induced by natural parasitic infection) included: provi-
sion of environmental enrichment stimulators (ameliorates mental 
harm), daily welfare and body condition checks (increasing 
to twice daily at day 45 post-infection) to avoid breaching the 
severity band of the project license and infection with a mini-
mal number of parasites to reduce the likelihood of developing 
more than moderately adverse effects.
Parasite material
The life cycle of the NMRI (Puerto Rican) strain of S. mansoni 
was maintained by routine infections of Mus musculus (Tuck 
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Ordinary - TO) female mice and Biomphalaria glabrata (NMRI 
albino and pigmented hybrid) snails. For collection of cercariae, 
infected snails were exposed to light in an artificially heated 
room (26°C) for 1 h. The cercarial suspension was subsequently 
mechanically transformed into schistosomula34 for in vitro 
compound screening or immediately used to percutaneously 
infect M. musculus (180 cercariae/mouse)35 for generation of adult 
schistosomes. The infected mice (six individuals per cage) 
were fed with rodents’ diet and water ad libitum and housed in 
a room (temperature 26°C and humidity ~70%) with 12 h light 
cycle (12 h on, 12 h off). Seven weeks post-infection, experi-
mental animals (18 mice) were euthanised with an intraperito-
neal administration of a non-recoverable dose (100 mg/kg) of 
sodium pentobarbital solution (10 mg/ml, JM Loveridge) contain-
ing heparin (100 U/ml solution in 1X PBS, containing 137 mM 
NaCl, 2.7 mM KCl, 10 mM Na
2
HPO
4
, and 2 mM KH
2
PO
4
). Upon 
loss of ocular and limb reflex responses to stimuli (4 min), para-
site material was obtained by hepatic portal vein perfusion with 
pre-warmed (37°C) perfusion media (DMEM supplemented with 
0.1% 100 U/ml heparin solution in 1X PBS). In brief, the 
abdominal cavity was opened and the hepatic portal vein was 
exposed and severed with a 23G needle. This was followed 
by administration of perfusion media into the left ventricle of 
the heart to flush worms out of the severed hepatic portal vein. 
Following perfusion, worms were washed by sedimentation with 
perfusion media first and then pre-warmed adult worm media 
(DMEM (Gibco, Paisley, UK) supplemented with 10% v/v 
FCS (Gibco, Paisley, UK), 1% v/v L-glutamine (Gibco, Paisley, 
UK) and an antibiotic mixture (150 Units/ml penicillin and 
150 µg/ml streptomycin; Gibco, UK)). Following incubation 
in a humidified environment containing 5% CO
2
 at 37°C for at 
least 1 h, adult worms were used for either in vitro compound 
screening or RNA interference (RNAi).
Infected livers from perfused mice were homogenised in 
double saline solution (1.7% w/v NaCl) using a Waring blender 
and the homogenates were passed through a 0.45 µm filter to 
retain egg material. Eggs were allowed to hatch in 1X Lepple 
water36 and the resulting miracidial suspension was enumer-
ated prior to being used for snail infections (12 miracidia/snail) 
or in vitro miracidia to sporocyst screens.
Homology modelling
The homology model of Smp_138030 was generated within 
the MOE 2015.1037 homology tool using a single template 
approach as previously described28. The program MODELLER 
could be a valid alternative for comparative protein structure 
modelling38. The template selected for this protein was the three-
dimensional structure of the catalytic domain (SET domain) of 
Homo sapiens MLL3 (PDB ID: 5F6K:C, 58% sequence similar-
ity). An induced fit option was selected to take into account the 
presence of histone H3, residues 2–7 (the peptide substrate39) 
and S-adenosyl homocysteine (SAH), the demethylated metabo-
lite of the cofactor SAM. Ten different intermediate models 
were built and minimised using Amber94 before refining the 
final model from a Cartesian average of the 10 generated inter-
mediates. The overall quality of the final model was evaluated by 
RAMPAGE Ramachandran Plot analysis40, ProSA-web41 and 
Verify3D42.
RNA interference and quantitative reverse transcription 
PCR (qRT-PCR)
RNA interference (RNAi), using synthetic short interfering 
RNAs (siRNAs), was performed as previously described10,28,43,44. 
Briefly, siRNA duplexes targeting smp_138030 and non-specific 
luciferase (Luc) were designed and purchased from Sigma 
(sequences reported in Table 1). Mixed sex adult worms 
electroporated with a final concentration of 50 ng/µl siRNA 
duplexes were next cultured at 37°C in adult worm medium 
(DMEM supplemented with 10% FCS, 2 mM L-glutamine, 10% 
v/v HEPES (Sigma-Aldrich, UK), 100 Units/ml penicillin and 
100 µg/ml streptomycin) in a humidified atmosphere contain-
ing 5% CO
2
; a 70% media exchange was performed every 48 h. 
Adult worms were cultured under these conditions for 48 h prior 
to assessing smp_138030 abundance by quantitative reverse 
transcription PCR (qRT-PCR). An additional set of worms was 
cultured for 72 h to detect variations in levels of H3K4 methyla-
tion in schistosome nuclear extracts/histone preparations. Addi-
tionally, a third set of worms was cultured for a total of seven 
days to monitor adult worm motility daily as well as to analyse 
fecundity (e.g. egg count). All experiments were replicated 
three times (15 worm pairs/replicate).
For qRT-PCR analyses, 48 h post-siRNA electroporation, 
worms were homogenised using a TissueLyser LT (Qiagen, UK) 
in TRIzol Reagent (Invitrogen, UK) before isolation of total 
RNA using the Direct-zol RNA Kit (R2050, Zymo, UK). cDNA 
was generated using SensiFAST cDNA synthesis kit (BIO-65053, 
Bioline) and qRT-PCR was performed with SensiFAST SYBR 
Hi-ROX mix (BIO-92005, Bioline) and specific qRT-PCR 
primers (listed in Table 1) for amplifying smp_138030 and the 
internal standard alpha tubulin (smAT1, smp_090120, used as 
a housekeeping gene)45. The reactions were conducted in a Ste-
pOnePlus Real-Time thermal cycler (Applied Biosystems). The 
comparative threshold Cycle (Ct) mode and Fast protocol was 
used with the following parameters: 95°C for 20 sec followed 
by 35 cycles of 95°C for 3 sec followed by 60°C for 30 sec. 
Table 1. Small interfering RNA (siRNA) and quantitative 
reverse transcription PCR (qRT-PCR) oligonucleotide 
sequences used in this study.
Target Small interfering RNA (siRNA) sequence
Smp_138030 CGUUUGGUCCCAUCGGACA[dT][dT] 
UGUCCGAUGGGACCAAACG[dT][dT]
Luciferase CUUACGCUGAGUACUUCGA[dT][dT] 
UCGAAGUACUCAGCGUAAG[dT][dT]
Target Quantitative Reverse Transcription PCR 
(qRT-PCR)
Smp_138030 FW: 5´-GTCTACCGGGTGTTCGACG-3´ 
RV: 5´-TCCAAATCCCGTGCAGC-3´
α-Tubulin 
Smp_090120 
(SmAT1)
FW: 5´-CTTCGAACCAGCAAATCAGA-3´ 
RV: 5´-GACACCAATCCACAAACTGG -3´
FW: forward; RV: reverse.
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The resulting data were analysed using the StepOne Software 
v2.1 (Applied Biosystems) as previously described10,45.
Detection of global H3K4 methylation
siSmp_138030 treated worms were maintained under normal 
laboratory conditions (5% CO
2
 at 37°C) for three days along-
side the siLuc controls (five worm pairs per well, 15 worm pairs 
per condition). Male and female worms were then separately 
homogenized with a TissueLyser (Qiagen) and total histones 
extracted using the EpiQuikTM Total Histone Extraction kit 
(OP-0006, Epigentek) following the manufacturer’s instructions. 
The concentration of each sample was quantified by Bradford 
assay prior to being processed with the EpiQuikTM Global His-
tone H3K4 Methylation Assay Kit (P-3017-96, Epigentek) to 
measure global histone H3K4 methylation levels.
The absorbance (OD) reading at 450 nm of each sample (15 
worm pairs per condition, three biological replicates each) was 
obtained using a POLARstar Omega (BMG Labtech, UK) micro-
titer plate reader. The percentage of H3K4 methylation was 
calculated according to the following equation:
        
( )
( )% 100%
OD sample blank
Methylation x
OD untreated control blank
−
=
−
        
where the untreated control and the blank were the luciferase 
controls and the buffer only, (provided in the kit), respec-
tively. The mean of the adjusted control values was set at 100% 
H3K4 methylation and the standard deviation (SD) was 
calculated from the normalised values.
Structure-based virtual screening (SBVS) framework
The structure-based virtual screening (SBVS) framework applied 
in this study was previously described28,46 and included four 
main steps: (1) target and library pre-processing, (2) docking, 
(3) scoring and (4) post-processing of top-scoring hits. In brief, 
a library of commercially available compounds (the fragment-
based library including 4,352 chemicals) was downloaded from 
Specs and processed by the Lig Prep tool within Maestro 
v10.147; AutoDock could alternatively be used for this function48. 
The target model (Smp_138030) was pre-processed using the 
Protein Preparation Wizard within Maestro (otherwise Auto-
Dock) by assigning bond orders, adding hydrogens and perform-
ing a restrained energy minimisation of the added hydrogens 
using the OPLS_2005 force field. Docking simulations were 
performed on the substrate binding pocket of the target to 
evaluate the binding affinity of each Specs compound to a 12 Å 
docking grid (inner-box 10 Å and outer-box 22 Å) previously 
prepared using, as a centroid, the substrate peptide.
Initially, the in silico molecular docking was performed using 
the Glide docking software within Maestro (Schrödinger 
Release 201747) using the standard precision function (SP; all 
4,532 compounds). AutoDock could be alternatively used as 
docking program. The results were subsequently refined using 
the more accurate extra precision (XP) function. The result-
ing conformations (or poses) of the compounds were ranked 
according to the Glide XP scoring function with the top 500 
distinct compounds identified and retained for a similar dock-
ing (both SP and XP) to the corresponding human homologue 
H. sapiens MLL3 (PDB ID: 5F6K), previously prepared as 
described above for the schistosome protein. As a result, each 
compound was associated with a pair of docking scores (the SP 
and XP scoring function) for both the schistosome and the 
corresponding human homologue. The compounds with a more 
favourable docking score (i.e. the lower energy value repre-
sented by more negative values for both XP and SP scores) 
for the parasite protein compared to the human template were 
selected. A subset of compounds (defined here as first set of 
compounds) was carefully chosen to encompass maximal chemi-
cal diversity and purchased for biological screens. Refinement 
of the first selection criterion led to the identification of chemi-
cals (defined here as second set of compounds) having a more 
favourable docking score for the parasite protein compared 
to the human template for at least one of the scoring function 
(either SP or XP score).
In a final stage of the study, we used the central scaffold of 
compound 7 (6-(piperazin-1-yl)-1,3,5-triazine-2,4-diamine, 
simplified molecular-input line-entry) as query structure to search 
for any remaining structural analogues of compound 7 present 
in the Specs fragment-based library. This structure-based search 
resulted in 17 compounds, of which nine chemicals were already 
included in the second set of compounds. The remaining eight 
small molecules were purchased and screened to fully explore 
the chemical space around the central scaffold of compound 7. 
These chemicals were not previously identified because they 
did not have a more favourable docking score (neither SP nor 
XP score) for the parasite protein compared to the human 
template. Overall, this approach exhaustedly investigated the 
whole Specs database for any closely structural related analogues 
of compound 7.
Schistosomula screens
Anthelmintic activity on the schistosomula stage of S. mansoni 
was evaluated using Roboworm, an integrated high-throughput, 
high content image analysis platform originally developed by 
Paveley et al.49 and subsequently used by our research group as 
previously described10,28,50,51. Alternatively, the computer appli-
cation Worminator can be used to assess motion of micro-
scopic parasites such as the schistosomula stage of S. mansoni52. 
Compounds (as single concentration or two-fold titrations) were 
prepared for screening in a 384-well plate (PerkinElmer, MA, 
USA), where solutions (1.6 mM, 0.5 µl) were wet stamped using 
the Biomek NXP liquid handling platform into Basch medium 
(20 µl)53. Negative (0.625% DMSO) and positive (Auranofin - AUR 
- at 10 µM final concentration in 0.625% DMSO) control wells 
were similarly prepared. Mechanically transformed schistosomula 
(about 120 parasites in 60 µl of Basch medium) were distrib-
uted into each treated well using a WellMate (Thermo Scientific, 
Loughborough, UK). Schistosomula/compound co-cultures were 
then incubated at 37°C for 72 h in a humidified atmosphere 
containing 5% CO
2
. At 72 h, parasite/compound co-cultures were 
resuspended and tissue culture plates were imaged under the 
same conditions (37°C for 72 h in a humidified atmosphere con-
taining 5% CO
2
)
 
using an ImageXpressXL high content imager 
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(Molecular Devices, UK) with subsequent images processed for 
phenotype and motility as previously reported49. Plate analysis 
returned a phenotype and motility score for each well and any 
scores below -0.15 and -0.35 (defined threshold anti-schistosomula 
values for phenotype and motility scores, respectively) defined 
a condition displaying anti-schistosomula activity. Compound 
screens were assessed based on the Z´ values (derived from 
the means and standard deviations of positive and negative 
controls54) and those equal to or above 0.3 for both phenotype 
and motility were considered successful.
Phenotype and motility scores of each titration were used to 
generate dose response curves in GraphPad Prism 7.02 based 
on the corrected average score of the three replicates for each 
data point. These data were then used to calculate EC
50
 (the 
concentration of compound that caused motility or pheno-
type defects in 50% of the treated parasite when compared to 
untreated controls) values.
Adult worm screens
For compound screening, adult worms (three worm pairs/well 
for compound 7 and the hit compounds of set two; one worm 
pair/well for the hit compounds of set three) were transferred 
into wells of a 48-well tissue culture plate containing 1 ml of 
adult worm media. Adult worms were treated with compounds 
previously identified as hits at 10 µM on 72 h cultured schis-
tosomula. Worms were dosed with an appropriate volume of 
10 mM stock solution of each compound (in DMSO) to have 
a concentration range of 50 – 6.25 µM (up to 0.5% DMSO, 
primary screen of compound 7). Secondary screens were per-
formed on the structural analogues of compound 7 (only the 
schistosomula hits at 10 µM) at a single concentration (12.5 µM) 
and compared to the same concentration of the parental com-
pound (included in the screen as reference). DMSO (0.5%) and 
praziquantel (10 µM in 0.5% DMSO) were also included as 
negative and positive control treatments (both primary and sec-
ondary screens). Treated adult worms were incubated for 72 
h in a humidified environment at 5% CO
2 
at 37°C. Parasite 
motility after drug treatment was assessed by a digital image 
processing-based system (WormassayGP2, see Software 
availability55) modified after Wormassay52,56,57. Egg production 
was assessed according to the methodology described by 
Edwards et al.58.
Miracidia screens
Following hatching of S. mansoni eggs, miracidia were incubated 
on ice for 15 min and then centrifuged at 700 x g for 5 min at 
4°C. The miracidia pellet was then re-suspended in 5 ml of 
Chernin’s balanced salt solution (CBSS), subjected to pellet-
ing and two subsequent washes (all at 700 x g for 5 min at 4°C). 
Afterwards, the supernatant was carefully removed with a sero-
logical pipette and the miracidia-enriched pellet was resuspended 
with CBSS supplemented with 1 mg/ml each of glucose and 
trehalose and 500 µl of Penicillin-Streptomycin (contain-
ing 10,000 units penicillin and 10 mg streptomycin/ml, P4333, 
Sigma-Aldrich)23. In preparation for the screens, CBSS (250 µl) 
was aliquoted to each well of a 24-well plate followed by addition 
of each compound in DMSO (1 mM concentration in 1% DMSO) 
or DMSO alone (1%, negative control). Next, approximately 
20-25 miracidia (in 250 µl of CBSS) were aliquoted to each 
well. A preliminary dose-response titration of compound 7 
(50, 25, 10, 5, 2 and 0.5 µM in 1% DMSO) was performed and 
secondary single-concentration (10 µM in 1% DMSO) screens 
of the most active (hits on schistosomula at 10 µM) structural 
analogues followed. Both preliminary and secondary screens 
were performed in duplicate on two separate occasions (two 
independent biological replicates). Miracidia were incubated for 
48 h at 26°C before being evaluated using an Olympus inverted 
light microscope for morphological and behavioural changes 
differing from the control wells. Dead, partially transformed and 
fully transformed miracidia were enumerated in the DMSO 
control and the assay plates as previously described5,23,59. In brief, 
parasites were visually scored “dead” if no macroscopic movement 
and flame-cell activity was detected and tegument/epidermal 
surface showed signs of degeneration. “Transforming” parasites 
were no longer swimming, had a “rounded” morphology and 
were in the process of shedding epidermal plates. Absence of 
ciliated plates attached to the surface of the parasite and 
formation of sporocyst tegument defined the so-called “fully 
transformed” parasites.
Cytotoxicity assay on human surrogate cell line (HepG2 
cells)
Compound cytotoxicity on Human Caucasian Hepatocyte 
Carcinoma (HepG2) cells (85011430, Sigma Aldrich) was elu-
cidated by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) tetrazolium reduction assay as previ-
ously described10,28,50. Briefly, HepG2 cells were seeded at a 
density of 20,000 per well in 96-well black, clear bottom falcon 
plate in modified BME medium (50 µl; containing 1% antibiotic/
mycotic (Sigma-Aldrich, Gillingham, UK), 1% 200 mM L-glutam-
mine (Gibco, Paisley, UK), 1% MEM non-essential amino acid 
solution (Gibco, Paisley, UK), and 10% fetal bovine serum (Gibco, 
Paisley, UK)). HepG2 plates seeded for cytotoxicity screens 
were treated with compounds 24 h post-seeding. Each compound 
was tested at 200, 100, 75, 50, 20, 10 and 1 µM; each concen-
tration was assayed in triplicate. Blank wells (no cells), as well 
as positive (1% v/v Triton X-100, X100, Sigma-Aldrich) and 
negative (1.25% v/v DMSO or media only) controls, were 
included in each plate. After addition of compounds, each plate 
was then incubated for a further 20 h before application of 
MTT reagent for assessment of compound cytotoxicity (4 h 
incubation with MTT for a total 24 h cell-drug incubation)60. 
The absorbance reading at 570 nm was measured with a 
POLARstar Omega (BMG Labtech, UK) microtiter plate reader. 
Dose response curves were generated in GraphPad Prism 7.02 
based on the corrected average absorbance of the three repli-
cates for each concentration point. These data were then used 
to calculate CC
50
 (the concentration of compound that reduced 
cell viability by 50% when compared to untreated controls) 
values.
Scanning electron microscopy to assess compound 
damage on adult worms
Following 72 h of drug treatment, the cultured S. mansoni adult 
worms were collected, separated by sex and relaxed with tric-
aine anaesthetic solution (0.25% w/v of ethyl 3-aminobenzoate 
methane sulfonate - Tricaine, E10521, Sigma Aldrich - in DMEM). 
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The samples were incubated by gently rocking for 15 min 
or until parasites relaxed and separated. The parasites were 
then killed by incubation in a solution of 0.6 mM magne-
sium chloride (MgCl
2
) for 1 min. Afterwards, adult schisto-
some worms were briefly washed with pre-warmed 1X PBS 
and then fixed using appropriate solutions for analysis by scan-
ning electron microscopy (SEM) as previously described in 
literature58,61,62.
Post fixation, adult schistosomes were stored at 4°C until wash-
ing with 0.1 M sodium cacodylate was performed (2 x 30 min 
each). The worms were then stained with 1% v/v osmium tetrox-
ide water solution (stored at -20°C and pre-warmed at room 
temperature prior to use) for 2 h and then washed with 0.1 M 
sodium cacodylate for 30 min. Following staining, worms were 
dehydrated with an aqueous alcohol series (30, 50, 70, 95 and 
100% ethanol in ultra-pure water) by agitating gently on a 
rocker for 30 min per solution. At the final step, the samples 
were left in 100% ethanol overnight before being dried with 
hexamethyldisilazane critical drying point agent (AGR1228, 
Agar Scientific, Stansted, UK) for at least 3 h.
Following critical point drying, the organic solvent was removed 
with a Pasteur pipette and the samples were left to dry over-
night. Samples were then placed onto self-adhesive conductive 
carbon tabs on aluminium specimen stubs (both Agar Scientific, 
Stansted, UK) and then were coated with gold using a Polaron 
E5000 SEM Coating Unit. Coated worms were then stored in 
a desiccation jar until imaging on a Hitachi S-4700 FESEM 
microscope using the Ultra High-Resolution mode and an 
accelerating voltage of 5.0 kV at a working distance of 5.0 mm.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 
7.02. In detail, comparisons between two or multiple groups 
were performed using Mann-Whitney U-test (Student’s t test, 
two tailed, unequal variance) and Kruskal-Wallis test followed 
by Dunn’s test, respectively.
Results
Homology model of Smp_138030
Schistosome genome analyses predicted a full set of SmHMTs 
and SmHDMs cooperatively regulating histone methylation in 
S. mansoni21,28. Among the 20 identified protein lysine methyl 
transferases (PKMTs), Smp_138030 was characterised as the 
closest homologue of the human mixed lineage leukemia (MLL) 
HMT; this schistosome protein will be referred to as SmMLL-1 
from this point forward (Figure 1). SmMLL-1 contains a SET 
domain, a post SET domain and FY-rich N/C terminal (FYRN 
and FYRC) sequence motifs (Figure 1A), which are particu-
larly common in histone H3K4 methyltransferases like MLLs63. 
SmMLL-1’s homology model was constructed using the catalytic 
domain (SET domain) of the human template MLL3 (Figure 1B). 
The global quality of each model was validated by Ramachan-
dran plot analysis, ProSA-web and Verify 3D (Supplementary 
Figure 1, Extended data64); all approaches surpassed agreeable 
standards defined in the literature41,65. Overall, these tools sug-
gested that Smp_000700/SmMLL-1’s homology model was of 
reasonable quality compared to the human MLL3 template 
and, thus, suitable for further experiments.
SmMLL-1’s SET domain (defined by SET-N, SET-I and SET-C, 
Figure 1A) contains a series of β stands, which fold into three 
discrete sheets around a unique knot-like structure (Figure 1B)66. 
In this structure, the SET domain C-terminus threads through a 
loop region, which is formed by a hydrogen bond between two seg-
ments of the protein chain67. The homology model of this PKMT 
shows the position of the four conserved motifs within the SET 
domain67. Motifs I and II are found within the SET-N domain, 
whereas motifs III and IV are found within the SET-C domain. 
Motif I (or GxG motif where x represents any amino acid, 
usually bulky hydrophobic residues) defines the cofactor bind-
ing pocket and most of the conserved residues of this motif are 
mainly associated with cofactor binding. Motif II is involved 
in the catalytic activity of these SET proteins and its arginine 
residue forms a salt bridge with a conserved glutamic acid in the 
SET-C region (Figure 1C) contributing to the structural stability 
of the protein. Motif III, containing the RFINHSCxPN sequence 
(where x represents any amino acid), is responsible for substrate 
recognition as well as the formation of the pseudoknot structure66 
with Motif IV (containing the GEELxxDY consensus sequence, 
where x represents any amino acid) located close to the 
C-terminus (Figure 1C).
Functional genomics investigation of Smp_130830/
SmMLL-1
RNAi-mediated post-transcriptional gene silencing was employed 
to explore the biological role of this SET-domain containing 
protein in adult worm motility and fecundity (Figure 2). qRT-PCR 
assessment of smp_138030 transcript abundance in siSmp_138030 
treated worms revealed a decrease of 60% when compared to 
siLuc treated worms at 48 h post-electroporation (Figure 2A). 
Despite some signs of distress immediately after electropora-
tion, all worms recovered and appeared robust up until seven days 
post-treatment (the last time point examined in this study). 
Examination using light microscopy showed no specific phe-
notypic differences between the luciferase control and the target 
RNAi worms; no death was observed, all parasites retained 
gut peristalsis (as indicated by haemozoin movement) but they 
partially lost adherence to the tissue culture wells. However, move-
ment was significantly reduced in siSmp_138030 treated worms 
at this time-point when compared to siLuc controls (Figure 2B). 
Daily measurements of worm movement were next assessed start-
ing at 24 h post electroporation and continuing until day seven 
(Figure 2C). By doing so, we observed a significant difference 
in worm movement between the control and the treated worms 
starting at day three and continuing up until day seven. In 
addition to this motility defect, smp_138030 knockdown also led 
to anti-fecundity effects. In fact, at day seven post siRNA treat-
ment, egg production was significantly inhibited (~40% reduced) 
in siSmp_138030 treated worms (Figure 2D). To assess whether 
a 60% smp_130830 knockdown resulted in a histone methyla-
tion defect in adult schistosomes, an ELISA-based assay quanti-
fying methylation on histone H3, lysine 4 (H3K4) was performed 
on adult worm (both male and female) histone protein extracts. 
These assays revealed that smp_138030 knockdown resulted 
Page 7 of 37
Wellcome Open Research 2020, 5:169 Last updated: 24 NOV 2020
Figure  1.  Smp_138030/SmMLL-1  is  a  SET  domain  containing  protein  lysine  methyltransferase  (PKMT). Panel  A  - Schematic 
representation of the domain architecture of Smp_138030 is reported with indication of the different domains. PHD zinc finger - Plant 
homeodomain zinc finger; FYRN - FY-rich domain N-terminal; FYRC - FY-rich domain C-terminal; Post-SET - post Su(var)3-9, Enhancer-of-
zeste and Trithorax domain. A focus of the SET domain contained in the homology model is provided: SET-N and SET-C domains (in green 
and blue, respectively) linked by a third domain (SET-I, in light brown). Panel B - Ribbon drawing of the structure of Smp_138030’s SET 
domain constructed using the homology modelling approach shows the different structural elements (SET-N, SET-I and SET-C) highlighted 
in different colours (same colour code used for Panel A). Panel C - Same orientation as in B, but highlighting the structural motifs I to IV in 
black. The N- and C-termini of the protein are labelled as ‘N’ and ‘C’, respectively. S-adenosyl homocysteine (SAH) is shown as spheres and 
sticks (grey for carbons, red for oxygen, blue for nitrogen); the peptide from histone H3 is represented as yellow ribbon (the methylated 
lysine is shown as grey stick). In Panel C, the two residues (the conserved arginine of Motif II and a conserved glutamic acid in the SET-C 
region) responsible of the salt bridge are shown in stick mode. All hydrogens are removed from all residues and chemical structures for 
clarity. Graphical representation of Panel A is created using IBS 1.0; images of Panel B and C are created using MOE 2015.10. The program 
MODELLER could be a valid alternative for comparative protein structure modelling.
in a 9% reduction (not statistically significant) of H3K4 
methylation (Figure 2E).
The identification of putative SmMLL-1 inhibitors and 
their activity on schistosomes
After establishing that SmMLL-1 was a druggable target by 
RNAi, a collection of seven compounds (Supplementary Table 1, 
Extended data64) with a more favourable docking score (both SP 
and XP score) for SmMLL-1 compared to the human template 
(MLL3) were screened for anti-schistosomula activity at 50 and 
10 µM (Figure 3). The calculated Z´ values for both phenotype 
and motility of the performed screens (summarised in Supple-
mentary Table 2, Extended data64) were within accepted ranges as 
previously described54. Among these compounds, two (compounds 
4 and 7, Table 2) showed anti-schistosomal activity (Figure 3A) 
at 50 µM with only compound 7 remaining active at 10 µM 
(Figure 3B). At 50 µM, compound 4 treated parasites presented 
an elongated phenotype similar to the Auranofin-treated schisto-
somula (Figure 3C). In contrast, compound 7 treated schistosomula 
(at both 50 and 10 µM) appeared swollen with some individuals 
additionally displaying posterior end compression (as shown in 
Figure 3C). A secondary anti-schistosomula titration of com-
pound 7, across four independent screens (Z´ values listed in 
Supplementary Table 2, Extended data64), was subsequently per-
formed to quantify its potency; here, EC
50 
values of 5.65 µM for 
phenotype and 5.03 µM for motility were obtained (Supplementary 
Figure 2, Extended data64).
The anti-schistosomal activities of compound 7 was next 
explored on adult worms (Figure 4). At 50 and 25 µM, the 
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compound had a lethal effect, however, worm recovery began 
at 12.50 µM and remained at 6.25 µM (Figure 4A). In terms 
of egg production, compound 7 was particularly effective 
in inhibiting worm fecundity up to and including 12.50 µM 
(Figure 4B).
Scanning electron microscopy was used to evaluate the mor-
phological changes induced by in vitro treatment of the parasite 
with a sub-lethal concentration (12.50 µM) of compound 7 
(Supplementary Figure 3A, B and C, Extended data64) compared 
to the control (Supplementary Figure 3D, E and F, Extended 
data64). The compound induced partial loss of tubercles and 
spines as well as tegument erosion (asterisks in Panel B) and 
ulcerations (red arrows in Panel C).
Anti-schistosomal activity of compound 7 structural 
analogues
Based on these preliminary data which led to the identification 
of compound 7, the results of the comparative docking study 
of the Specs library were subsequently explored with a less 
stringent criterion in this second stage of the study. This led 
to the identification of a second set of compound 7 analogues 
(see Supplementary Table 3, Extended data64) with a bet-
ter predicted binding affinity to the substrate binding site of 
SmMLL-1 compared to its closest human homologue MLL3 
(PDB ID: 5F6K), based either on SP or XP docking score 
(i.e. at least one scoring function, conversely to the first 
selection of compounds where both conditions had to be 
satisfied).
Figure 2. RNAi-mediated knockdown of smp_138030/smmll-1 affects worm movement, in vitro production of schistosome eggs 
and H3K4 methylation. Panel A - Seven-week old adult male and female schistosomes were electroporated with 5 μg siRNA duplexes 
targeting luciferase (siLuc) or smp_138030 (siSmp_138030). Following 48 h, total RNA was harvested and subjected to qRT-PCR. Percent 
knockdown (KD) and statistical significance (Student’s t test, two tailed, unequal variance - Mann-Whitney U-test) is indicated. All siRNA and 
qRT-PCR DNA sequences are included in Table 1. Panel B - Five worm pairs for each treatment (siLuc and siSmp_138030, repeated three times; 
n = 15 per sex per treatment) were cultivated for seven days post treatment in an atmosphere of 5% CO2 with a 70% media exchange performed 
every 24 h. Quantification of worm movement was performed using WormassayGP2 (see Software availability55) on the 7th day. Panel C - 
Daily movement of siRNA treated worms quantified by WormassayGP2. Panel D - Egg production at 168 h after introduction of siRNAs. 
Panel E - Following RNAi-induced smp_138030 knockdown, total histone extracts from RNAi targeted worms (siSmp_138030) and control 
worms (siLuc) were analysed for H3K4 methylation. The bar chart represents the average H3K4 methylation detected in male and female 
pairs as there was no statistical significance between sexes. Statistical significance is indicated (Student’s t test, two tailed, unequal variance 
- Mann-Whitney U-test). *, ** and *** represent p < 0.05, p < 0.01  and p < 0.001, respectively.
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Figure  3. Putative SmMLL-1 substrate-binding pocket inhibitors (set one) affect schistosomula phenotype and motility. 
Mechanically-transformed schistosomula (n = 120) were incubated with the selected compounds (50 µM - Panel A - and 10 µM - Panel B 
- in 0.625% DMSO; each of them in duplicate) for 72 h at 37°C in a humidified atmosphere containing 5% CO2. One of three replicate screens 
is shown here (barcode 0255, Supplementary Table 2, Extended data64). Compounds with activity on both schistosomula phenotype and 
motility are shown within the ‘Hit Zone’ (delineated by the dotted red lines in the graph). Panel C - Visual representations of schistosomula 
phenotype induced by compounds 4 and 7. These two compounds were tested on schistosomula at 50 and 10 µM. Each image represents 
a cropped sample of the schistosomula obtained from hit wells of screen 0255. The brightness of the image has been modified slightly 
(+ 20%) from the original image to make the differences in phenotype more apparent. Images of control parasites - Auranofin, DMSO and 
media treated schistosomula - are included for reference.
Table 2. Docking results of human and schistosome proteins with the 
two selected compounds.
Compound Structure
Binding affinity 
with schistosome 
target (kcal/mol)
Binding affinity 
with human 
target (kcal/mol)
SP XP SP XP
4 -6.279 -7.058 -5.981 -5.909
7 -6.297 -7.86 -5.018 -5.176
Compound 4 and 7 were docked to the schistosome Smp_138030 and the closest 
human homologue (MLL3, PDB ID: 5F6K). SP - standard precision; XP - extra precision.
This second compound family encompassed nine structural ana-
logues of compound 7 and these were initially tested on schis-
tosomula at 50 and 10 µM (Figure 5, Z´ values summarised in 
Supplementary Table 4, Extended data64). Six out of nine tested 
compounds were hits on the larva stage of the parasite at both 
50 and 10 µM (Figure 5A and B), except for compound 14, 
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Figure 4. The most potent anti-schistosomula compound (7) affects adult worm motility and egg production. A dose response 
titration (50 - 6.25 µM) of compound 7 was performed to assess its potency on S. mansoni adult worms (three worm pairs/well for each 
condition). Panel A - Schistosome motility was quantified using WormassayGP2 at 72 h. Panel B - Eggs were collected and enumerated 
by brightfield microscopy at 72 h. Each titration was performed in three independent screens. A Kruskal-Wallis ANOVA followed by Dunn’s 
multiple comparisons test was performed to compare each population mean to DMSO mean value. ** and *** represent p < 0.0055 and 
p < 0.0003, respectively.
Figure  5.  Compound  7  structural  analogues  (set  two)  demonstrate  more  potent  anti-schistosomal  properties. Mechanically-
transformed schistosomula (n = 120) were incubated with the selected compounds (50 µM - Panel A - and 10 µM - Panel B - in 0.625% DMSO; 
each of them in duplicate) for 72 h at 37°C in a humidified atmosphere containing 5% CO2. One of three replicate screens is shown here 
(barcode 0329, Z´ scores are reported in Supplementary Table 4, Extended data64). The screen and the interpretation of the data is 
described in Figure 3.Compounds with activity on both schistosomula phenotype and motility are shown within the ‘Hit Zone’ (delineated 
by the dotted red lines in the graph). Panel C - Six compounds (8, 9, 12, 13, 15 and 16) were incubated with adult worms (three worm 
pairs/well for each condition)  at 12.5 µM (sublethal concentration for 7, here reported as reference) to assess their effect on motility 
at 72 h. Each screen was performed in duplicate in two independent screens. The effect on schistosome motility was quantified 
using WormassayGP2 (see Software availability55). Panel  D - After 72 h of drug treatment, eggs were enumerated. The egg count for 
each concentration tested is reported in the scatter chart. For each concentration tested, the mean egg count and the standard error 
across the two biological replicates with two technical replicates each is represented on the graph. Statistical analysis was performed 
similarly to Figure 4. *, **, *** represent p < 0.0208, p < 0.0055, p < 0.0003, respectively.
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which was only active at 50 µM. All compound 7 analogue hits 
at 10 µM were tested at lower concentrations to assess their 
anthelmintic potencies; EC
50
 values were derived from these 
dose response titrations (Table 3).
Among this second family of compound 7 analogues, only 
the small molecules demonstrating anti-schistosomula activ-
ity at 10 µM were subsequently screened against adult worms 
(Figure 5C). Specifically, they were only tested at 12.50 µM (the 
sublethal concentration for compound 7) in order to identify 
those with improved anthelmintic activity over compound 7. This 
comparative approach identified four compounds (compound 8, 
12, 15 and 16) as more potent than the original hit compound. 
Moreover, all tested compounds demonstrated a negative 
effect on schistosome fecundity with compounds 8, 12 and 15 
reducing egg production similarly to compound 7 (Figure 5D).
Anti-schistosomal activity of remaining compound 7 
structural analogues
In a final stage of the study, any other remaining compounds 
commercially available through Specs containing the central 
compound 7 scaffold (using 6-(piperazin-1-yl)-1,3,5-triazine-2,4-
diamine as query structure in Specs database) were next selected 
(without any docking score-based selection, Supplemen-
tary Table 5, Extended data64) and tested on in vitro cultured 
schistosomes (Figure 6). This third set of compounds was 
initially tested on schistosomula and, while five chemicals 
(17,20, 22, 23 and 24) were active at the highest concentration 
(50 µM) (Figure 6A), only three of them (20, 23 and 24) 
remained active at 10 µM (Figure 6B). The calculated Z´ values 
for both phenotype and motility of all schistosomula screens, 
related to this family of compound 7 analogues, are summarised 
in Supplementary Table 6 (see Extended data64). Compounds 
Table 3. Biological properties of compound 7 and its structural 
analogues.
Schistosomula EC50 (µM) Adult EC50 
(µM)
CC50 (µM)
Compound Phenotype Motility Average HepG2 cells
7 5.65 5.03 5.34 11.02 13.65
8 3.27 4.98 4.12 N.D. 14.88
9 3.39 3.6 3.50 N.D. 28.34
10 > 50 N.D. N.D.
11 > 50 N.D. N.D.
12 4.57 4.41 4.49 N.D. 10.98
13 4.70 4.82 4.76 N.D. 17.86
14 > 10 N.D. N.D.
15 1.09 1.79 1.44 N.D. 23.86
16 2.63 3.37 3.00 N.D. 54.18
17 > 10 N.D. N.D.
18 > 50 N.D. N.D.
19 > 50 N.D. N.D.
20 3.47 4.93 4.20 N.D. >100
21 > 50 N.D. N.D.
22 2.09 1.64 1.87 N.D. 93.55
23 3.06 2.79 2.92 N.D. 6.73
24 1.57 1.81 1.69 N.D. 3.31
Schistosomula EC50 (phenotype, motility and average of both metrics) values are calculated 
based on three dose response titrations (10 - 0.625 µM). Where no effect is seen on 
schistosomula at the highest concentration tested (50 µM), the EC50 is said to be more 
than 50 µM. The EC50 is said to be more than 10 µM if the compound is defined as a hit at 
50 µM but not at 10 µM. Adult worm EC50 value is calculated based on two dose response 
titrations (100 – 3.13 µM). The CC50 values are calculated based on three dose response 
titrations (200 - 1 µM) using the HepG2 cell line. All data are analysed using GraphPad 
Prism. N.D.: not determined.
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20, 23 and 24 were subsequently tested at lower concentra-
tions to assess their anthelmintic potencies; EC
50
 values were 
derived from these dose response titrations (Table 3).
These three compounds (20, 23 and 24) were next screened 
against adult worms at 12.50 µM (the sub-lethal concentration of 
parental compound 7) and all demonstrated greater potency than 
compound 7 in inhibiting motility and egg production at this 
concentration (Figure 6C). These compounds were subsequently 
screened at a lower concentration (6.25 µM) aiming to discrimi-
nate the most potent compound amongst this third set of small 
molecules (Figure 6D). This screen confirmed strong anthelmintic 
activities (motility and oviposition defects) for all compounds 
in comparison to the parental compound and indicated that 
compound 24 was the most potent.
Miracidial transformation is inhibited by compound 7 
and its structural analogues
To further assess the broader activities of these putative 
SmMLL-1 inhibitors on schistosome development, we next tested 
their ability to inhibit miracidia to sporocyst transformation 
(Figure 7). Firstly, compound 7 demonstrated a clear dose-
dependent effect on miracidia to sporocyst transformation; here, 
compound 7 was completely lethal to miracidia at 50 and 25 µM, 
whereas at 10 µM, compound 7 inhibited miracidia to sporo-
cyst transformation by 45% (Figure 7A). Inhibition of miracidia 
Figure 6. Anti-schistosomal activity of the remaining compound 7 analogues found within the Specs fragment-based library. 
Mechanically-transformed schistosomula (n = 120) were incubated with the selected compounds (50 µM - Panel  A - and 10 µM - 
Panel B - in 0.625% DMSO; each of them in duplicate) for 72 h at 37°C in a humidified atmosphere containing 5% CO2. One of the three 
independent performed screens is shown here as a representative of the preliminary larva screen (barcode 0358, Z´ scores are reported 
in Supplementary Table 6, Extended data64). The screen and the interpretation of the data is described in Figure 4. Compounds with activity 
on both schistosomula phenotype and motility are shown within the ‘Hit Zone’ (delineated by the dotted red lines in the graph). Three 
compounds (20, 23 and 24) were tested on adult worms at 12.5 µM (sublethal concentration for compound 7, here reported as reference, 
Panel C) and 6.25 µM (Panel D) to assess their potency on S. mansoni adult worms (one worm pair/well for each condition). Each screen 
was performed in duplicate in two independent screens. The effect on schistosome motility was quantified as described above using 
WormassayGP2. After 72 h of drug treatment with 3 structural analogues at 12.5 µM (scatter plot, Panel C) and 6.25 µM (scatter plot, 
Panel  D), eggs were enumerated. The hit compound 7 is included in the screen as reference. The egg count for each concentration 
tested is reported as a scatter chart. For each concentration tested, the mean egg count and the standard error across the two biological 
replicates with two technical replicates are represented on the graph. Statistical analysis (in black for the motility, in orange for the egg 
count) was performed similarly to Figure 4. **, ***, **** represent p < 0.0055, p < 0.0003, p < 0.0001, respectively.
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transformation declined to about 20–25% when the compound 
was tested at lower concentrations (5, 2 and 0.5 µM, Figure 7A). 
When the most active compound 7 analogues (compounds 
8, 9, 12, 13, 15, 16, 20, 23 and 24) were next tested at 10 µM, 
all readily killed miracidia except for compounds 15 and 16 
(Figure 7B).
Cytotoxicity of compound 7 and its structural analogues 
on HepG2 cells
Overt cytotoxicity was next explored on human HepG2 cells 
by prioritising those compounds that showed the most potent 
anti-schistosomal activities (EC
50
 on schistosomula equal or below 
10 µM) starting from parent compound 7 and extending into 
its structural analogues. Each compound was tested in a dose 
response titration (200 to 0.01 µM) with the average CC
50
 of each 
compound reported in Table 3. Compound 20 was not toxic to 
this cell line, except for concentrations above 100 µM. In contrast, 
compounds 23 and 24 showed the highest toxicity (CC
50
 below 
10 µM). All other compounds showed a range of moderate 
(10 µM < CC
50 
< 20 µM) to low (20 µM < CC
50 
< 60 µM) cytotoxic-
ity on the selected cell line.
Discussion
Careful regulation of histone methylation/demethylation is 
essential for developmental progression of the major human 
pathogen S. mansoni10,24,25,36. Therefore, exploration of the 
histone methylation machinery for druggable targets has been 
actively pursued10,28,29. Here, we contribute to these studies by 
demonstrating that the S. mansoni histone methyltransferase 
Mixed Lineage Leukemia homologue (SmMLL-1, Smp_138030, 
Figure 1) is one such druggable epigenetic target.
The first evidence of SmMLL-1’s druggability came from 
functional genomics investigations of the transcript in adult 
schistosomes (Figure 2). Here, partial siRNA-mediated knock-
down of smmll-1 (60%) resulted in adult worms physically 
detaching from the culture wells, moving significantly less and 
producing fewer eggs over a seven-day period post-treat-
ment. While other phenotypic changes (e.g. coiled worms) 
did not accompany these siRNA-mediated effects, knockdown 
of the same target in a large-scale RNAi investigation con-
firmed a similar detachment phenotype for this target in adult 
schistosomes57.
Consistent with our observations, functional genomics-led inves-
tigations have previously identified important roles for MLL 
homologues in other metazoans. In a variety of RNAi studies 
exploring set-16 (MLL homologue) function in C. elegans, 
diverse phenotypes were observed including larval lethality68, 
multivulva69, disorganized oocytes70, slow growth67 and sterility71. 
Overall, set-16 was confirmed as an essential gene even though 
some reported RNAi phenotypes provide evidence that not all 
MLL deficiencies are lethal72. Furthermore, distinct develop-
mental defects have been observed in MLL1-/- or MLL2-/- mice 
whereas embryonic lethality resulted from MLL3, -4, and -5 
deficiencies (observed in knockout mice)73,74. In the single cell 
eukaryote Saccharomyces cerevisiae, deletion of set-1 (homo-
logue of the human MLL-like protein) revealed a slow-growth 
defect75. Collectively, these data suggest that H3K4 methylation 
(mediated by MLL homologues) has pleiotropic effects and the 
downstream phenotypic consequences of this epigenetic mark’s 
dis-regulation may depend on the organism in which it is 
studied. This explanation could justify our siRNA-mediated 
knockdown results highlighting that SmMLL-1 is not essential 
for schistosome viability, but is critical to other parasite features 
important for lifecycle maintenance, including motility (to retain 
position in the mesenteric venules of the definitive host57) and 
fecundity. However, we cannot exclude that a more significant 
Figure  7.  Compound  7  and  its  most  active  structural  analogues  block  miracidia  to  primary  sporocyst  transformation. 
Panel A - The effect of compound 7 (50, 25, 10, 5, 2 and 0.5 μM) on miracidia transformation was registered in terms of % fully transformed 
sporocysts enumerated after 48 h. Each treatment was set up in triplicate and parasites were cultured in CBSS with 1% DMSO at a controlled 
temperature of 26°C (in the dark). Panel  B  - A drug screen was performed to assess the effect of compound 7 analogues at 10 μM 
to block miracidial transformation compared to the lead compound and DMSO (negative control). Statistical analysis was performed 
similarly to Figure 4. **, *** represent p < 0.0055, p < 0.0003, respectively.
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phenotype would be observed if a greater knockdown (above 
60%) was achieved.
Based on the structural and functional characterisation of this 
target suggesting that SmMLL-1 (Smp_138030) was likely to 
function as a protein lysine methyltransferase (PKMT) with a 
currently unknown catalytic specificity, an antibody-based assay 
was used for measuring global histone H3K4 methylation in si 
Smp_130830 treated worms. Here, only a slight decrease (9%) in 
global H3K4 methylation was observed in siSmp_130830 
treated worms compared to siLuc controls (Figure 2E). As other 
related PKMTs are found in the S. mansoni genome (Smp_144180, 
Smp_070170 - closely related to MLL proteins - and Smp_140390 
- closely related to the human SET1A/B)28,76, functional redundancy 
in the histone code could compensate for the minimal decrease 
in H3K4 methylation observed in si Smmll-1 treated worms, 
similarly to what has been observed in H. sapiens77,78. Moreo-
ver, SmMLL-1’s main enzymatic substrate could be non-histone 
proteins found in the cytoplasm as has been recently shown for 
other PKMT homologues79–81. Therefore, a more detailed inves-
tigation of siRNA-mediated changes in SmMLL-1’s epitope 
(e.g. lysine methylation) on both nuclear and cytoplasm frac-
tion derived from si Smp_130830 treated parasites could be very 
informative in this regard. Nevertheless, it is clear from these 
functional genomics investigations that SmMLL-1 is involved in 
aspects of adult worm biology essential for mesenteric blood 
vessel positioning (attachment and coordinated movement) as 
well as lifecycle transmission (oviposition).
To progress the identification of small, drug-like molecules 
capable of binding to and inhibiting the activity of SmMLL-1, 
iterative structure-based virtual screening (SBVS) was applied. 
In the field of neglected tropical diseases, this approach has been 
widely used by multiple academic and industrial groups in drug 
discovery and is becoming an essential tool for assisting rapid 
and cost-efficient lead discovery82. Successful applications of 
this approach for the discovery of novel anti-schistosomal agents 
include the identification of purine nucleoside phosphorylase-, 
tyrosine kinase-, 3-Oxoacyl-ACP reductase- and histone deacety-
lase- inhibitors83–85. For the work presented here on SmMLL-1, 
we focused on identifying compounds predicted to bind to 
the substrate-binding pocket over the cofactor-binding site 
since the former is usually less structurally conserved between 
functionally distinct proteins86.
The putative inhibitors identified in this study were initially 
screened on schistosomula at 10 and 50 µM. The 10 µM con-
centration defines a cut-off value for the selection of hit com-
pounds for further exploration in other lifecycle stages51, whereas 
the 50 µM screen was included to avoid the loss of chemical infor-
mation for exploring SAR and/or medicinal chemical optimisa-
tion. Compound 7 and its structural analogues (second and third 
set) shared the same 1,3,5-triazine (also called s-triazine) core 
linked to a piperazine ring (Supplementary Figure 4, Extended 
data64), which interestingly was also present in the anti-bil-
harzial drug Bilharcid87 and the protein kinase (PK) inhibi-
tor Imatinib88. The latter led to potent in vitro anti-schistosomal 
activity, which was lost in vivo likely due as a result of interaction 
with α-1-acid glycoprotein and serum albumin. Furthermore, a 
family of structural related derivatives (1,2,4-triazine) were also 
associated with anti-schistosomal activity89, although limited 
information is currently available related to mechanism of action.
The different patterns of piperazine ring substitution facilitated 
compound groupings (18 chemical entries in total) into two 
subfamilies: the monosubstituted-piperazines (N-substituted, 
Supplementary Figure 4A, Extended data64) and the disubsti-
tuted-piperazines ((N,N’)-disubstituted piperazine, Supplementary 
Figure 4B, Extended data64). The biological (schistosomes and 
HepG2 cells) screening of these compounds led to the definition 
of some preliminary SAR. Firstly, the presence of at least an 
aromatic ring linked to the triazine core generally increased the 
potency of the compounds (17 vs 7 and 10 vs 22, Figure 8A). 
However, compounds containing a double aromatic ring sub-
stitution did not seem to be as active as compounds containing 
a mixed ring substitution (one aromatic ring and one aliphatic 
ring (8 vs 7 and 8 vs 22). Moreover, the introduction of a spacer 
(N-linker) between the triazine core and the aromatic ring 
negatively affected the activity of these chemicals (8 vs 12, 
Figure 8E).
Once the importance of an aromatic ring linked to the 1,3, 
5-triazine core was established, the correlation between anti-
schistosomal activity and different ring substitutions in the sec-
ond substitution was investigated. In summary, aliphatic rings 
containing heteroatoms (e.g. morpholine in 15 and piperazine 
in 24) were usually more active than the cyclohexyl ring (23, 
Figure 8B). The effect of alkyl substituents (a methyl group in this 
case, in orange Figure 8C and D) on the aromatic ring was inves-
tigated, leading to the conclusion that ortho-methyl substitu-
tion of the ring (14 vs 22 and 13 vs 8) reduced in vitro activity. 
However, the para-methyl substitution correlated with slightly 
improved activity (15). Moreover, compounds with a substitu-
tion of the piperazine ring (11, 21, 19 and 18, Figure 9A) showed 
activity only at high concentration (EC
50
 > 50 µM), with the 
exception being compound 20 (EC
50
 = 4.20 µM). Nevertheless, 
only a few compounds carrying a substitution on the pipera-
zine ring were screened in this study, hence limited information 
is currently available to further inform and expand the prelimi-
nary SAR diagram of the compounds shown within this study 
(Figure 9B). It is noteworthy that all compounds investigated 
in this study have a nitrogen in positions 2 and 4 of the triazine 
ring either included in a ring (e.g. substitution with pyrrolidine, 
morpholine and piperidine) or as linker (i.e. an aryl amino sub-
stitution shown in magenta in Figure 9B). This observation 
leaves space for further exploration of this structural feature, 
which would provide more insight on the pharmacophore of 
this family of anti-schistosomal compounds.
Docking simulations (Supplementary Figure 5, Extended data64) 
to explore the putative binding mode of the central scaffold 
(6-(piperazin-1-yl)-1,3,5-triazine core) of these compounds to 
SmMLL-1’s substrate binding pocket confirmed a good fit 
(Supplementary Figure 5A, Extended data64). Here, the triazine 
core consistently occupied the entrance of the lysine channel 
(Supplementary Figure 5B, Extended data64) and engaged in 
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Figure 8. Structural activity relationship (SAR) of compound 7 analogues. Chemical structures of the compounds were analysed to 
investigate the effect of different chemical groups (corresponding to highlighted regions in cyan in Panel A, magenta in Panel B, orange in 
Panel  C and D, blue in Panel  E) on anti-schistosomula activity. EC50 values (derived from Table 3) were also reported for activity 
comparison.
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Figure 9. SAR of compound 7 analogues’ piperazine ring substitutions. Panel A - Chemical structures were analysed to investigate 
the effect of piperazine ring substitutions (corresponding to regions highlighted in orange) on schistosomula activity. Panel B - Summary of 
the SAR studies performed on the compounds presented in this study. A total of 18 structural analogues were used to generate this map. 
All biological results regarding the anti-schistosomal activity (EC50 values) were derived from Table 3.
arene-arene interactions with aromatic residues of the target 
(generally Phe1476 of Motif II of the SET domain, Supplementary 
Figure 5C, Extended data64). The piperazine ring fitted in the 
lysine channels pointing towards the SAH cofactor and engaged 
with Ile1473 (Motif II) by a hydrogen bond. The other two rings 
linked to the triazine core occupied two additional pockets of 
the substrate binding pocket and adopted different conforma-
tions according to the different substitutions found for each 
compound.
The application of homology modelling and in silico virtual 
screening to this schistosome target resulted in the identification 
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of novel anti-schistosomal compounds with a more favourable 
hit rate than what would be expected from a traditional 
high-throughput screening campaign90. The selection criteria 
based on the compound docking score (used for the identifica-
tion of the first and second set of chemicals) allowed us to address 
preliminary parasite-host selectivity considerations. In fact, 
the first (1–7) and second (8–16) set of compounds (Supplemen-
tary Table 1 and 3, respectively, see Extended data64) all showed 
potent anti-schistosomal activity (EC
50
 < 10 µM) and moderate to 
low cytotoxicity on HepG2 cells (CC
50
 > 10 µM, Table 3). Amongst 
the final set of compounds (17–24, Supplementary Table 5, 
Extended data64), two of the four hits at 10 µM (compounds 24 
and 23) showed the highest toxicity; this could be explained 
by a higher affinity of these chemicals to the human homologue 
(HsMLL3) over SmMLL-1, which was an exclusion factor 
used during the initial selection of compounds 1-16. However, a 
docking score-based approach has some limitations as we would 
have missed information on active compounds 20, 22, 23 and 24 
with EC
50
 < 10 µM. To overcome this, we applied an integrative 
methodology in this study. Firstly, compounds were selected 
based on docking simulation scores (difference in schistosome vs 
host target binding) and, secondly, extended to the exploration 
of chemical space around the central anti-schistosomal hit 
scaffold. We felt this approach provided the most effective way 
of identifying putative SmMLL-1 inhibitors containing a 
1,3,5-triazine core with a piperazine ring regardless of host cyto-
toxicity or docking software limitations (e.g. approximated 
scoring functions, which often provide computational results that 
do not correlate with experimental readouts)91,92.
With broad activity against miracidia, schistosomula and 
adults (aligned to smmll-1/smp_138030’s transcript abundance 
throughout the schistosome lifecycle28), this compound class was 
equally effective in halting key transitions in schistosome devel-
opment (Figure 3, Figure 4, Figure 5, Figure 6 and Figure 7). A 
notable activity against adult worms was observed since both motil-
ity and egg production were both significantly impaired (Figure 4, 
Figure 5 and Figure 6). These defects recapitulated the smmll-1 
knockdown phenotypes (Figure 2) and further validated SmMLL-1 
as a molecular target of this compound class. However, we can-
not rule out the possibility that the anti-parasitic activities of 
these compounds, at least in part, may have been due to inhibi-
tion of other SmHMTs or completely different targets within the 
parasite. As damage to the adult surface was observed during 
sub-lethal compound treatment (e.g. compound 7; Supple-
mentary Figure 3, Extended data64), but not observed during 
sismmll-1 RNAi studies, this hypothesis is currently under 
investigation.
In summary, using a combination of drug-discovery approaches, 
we have identified a novel chemical scaffold (the 6-(piperazin-
1-yl)-1,3,5-triazine) predicted to bind to SmMLL-1’s substrate 
binding pocket. Central features associated with this scaffold’s 
anti-schistosomal potency include both a triazine ring usually 
substituted with a combination of an aliphatic ring (or a het-
erocycle) and an aromatic ring (with a para rather than an ortho 
substitution). Further medicinal chemistry optimisation should 
be advanced to identify other aromatic ring/piperazine ring 
substitutions or different linkers connecting the triazine core 
to other portions of the molecule. By doing so, the progres-
sion of a chemical scaffold, not previously associated with 
anti-schistosomal activity, could lead to the development of a 
new therapeutic targeting a critical epigenetic enzyme.
Data availability
Underlying data
Figshare: Identification of 6-(piperazin-1-yl)-1,3,5-triazine as 
a chemical scaffold with broad anti-schistosomal activities – 
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This project contains the following underlying data:
•    1. RNAi-mediated knockdown of smp_138030/smmll-
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•    2. Schistosomula drug screen of putative SmMLL-1 
inhibitors.xlsx
•    3. Adult worm drug screen of putative SmMLL-1 inhibitors.
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•    5. Anti-schistosomula activity of the remaining compound 
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•    8. Schistosomula titration of compound 7.xlsx
•    9. SEM images.pptx
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Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
Extended data
Figshare: Identification of 6-(piperazin-1-yl)-1,3,5-triazine as 
a chemical scaffold with broad anti-schistosomal activities – 
Extended data. https://doi.org/10.6084/m9.figshare.12546449.v264.
This project contains the following extended data:
•    Supplementary Table 1 (List of putative SmMLL-1 
inhibitors (first set) identified by structure-based virtual 
screening)
•    Supplementary Table 2 (Phenotype and motility Z´ 
values for both primary (single-point concentration) and 
secondary (titration) screens of compound set one)
•    Supplementary Table 3 (List of compound 7 structural 
analogues (second set) identified as putative SmMLL-1 
inhibitors by structure-based virtual screening)
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•    Supplementary Table 4 (Phenotype and motility Z´ 
values for both primary (single-point concentration) and 
secondary (titration) screens of compound set two)
•    Supplementary Table 5 (List of remaining compound 7 
analogues available in the Specs fragment-based library)
•    Supplementary Table 6 (Phenotype and motility Z´ 
values for both primary (single-point concentration) and 
secondary (titration) screens of remaining compound 7 
analogues available in the Specs fragment-based library)
•    Supplementary Figure 1 (The homology model of SmMLL-
1/Smp_138030 is of high quality according to three 
different metrics)
•    Supplementary Figure 2 (Compound 7 demonstrates 
moderate anti-schistosomula potency)
•    Supplementary Figure 3 (A sub-lethal concentration of 
compound 7 induces surface and tegumental alterations in 
adult schistosomes)
•    Supplementary Figure 4 (Chemical structure and anti-
schistosomal properties (EC
50
s) of the 18 compounds 
investigated in this study)
•    Supplementary Figure 5 (Hypothetical binding mode 
of the compound 7 analogues to the predicted target 
SmMLL-1)
Data are available under the terms of the Creative Commons 
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Padalino et al. used a multidisciplinary approach (functional genomics, molecular modeling and 
efficacy studies on different developmental stages of S. mansoni) for the discovery of novel targets 
and drugs for the treatment of schistosomiasis. Schistosomiasis is a neglected tropical parasitic 
disease affecting more than 200 million people in the poorest regions of the world. Today, the 
treatment and most control initiatives for schistosomiasis rely on a single drug, praziquantel (PZQ) 
that has high efficacy, few and transient side effects, competitive cost. However, while very active 
on adult parasites, PZQ is poorly effective against juvenile worms both in vitro and in vivo. 
Moreover, the constant and massive use of a single drug has raised concerns about the possibility 
of emerging drug resistance. Therefore, the discovery of new drug targets and compounds is 
required. Targeting the epigenome has emerged as a new strategy for the treatment of parasitic 
diseases including schistosomiasis. 
 
The present study identifies a novel potentially relevant drug target, a histone methyl transferase 
(HMT), SmMML-1 in Schistosoma mansoni. Moreover, new multi-stage active compounds were 
identified and characterized. 
 
Overall the work is well written, the study is well hypothesized, designed and executed. The results 
support the majority of the conclusions. Unfortunately, it is not clear at this stage whether the 
novel compounds are acting on the MLL-1 homologue in S. mansoni. I think the following 
suggestions could help you to address this open issue.
Smp_138030 was characterized as the closest homologue of the human mixed lineage 
leukemia (MLL) HMT. Silencing of Smp_138030 (60%) resulted in motility and egg production 
defects in adult worms; however, no statistically significant change of H3K4 methylation was 
detected in knockdown parasites. This finding suggests that the MLL-1 homologue in S. 
mansoni might target different enzymatic substrates and/or that silencing of other HMT 
genes is required to impair H3K4 methylation in S. mansoni. 
Gene expression studies of siLuc and siSmp_138030 parasites could lead to the 
identification of a SmMLL-1-associated signature. In turn this signature could be compared 
○
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with the one derived from compound 7 and compound 7 analogs-treated parasites in order 
to support the hypothesis that the novel compounds are targeting SmMLL-1; 
 
Viability assays and phenotyping studies could be performed in siLuc 
and siSmp_138030 parasites treated with sub-lethal or lethal doses of compound 7. 
Differences in the gene-silenced compound-treated parasites could support the hypothesis 
that the novel schistosomicidal compound is targeting SmMLL-1; 
 
○
H3K4 methylation should be also investigated in parasites treated with compound 7 and/or 
its structural analogues; 
 
○
H3K4 methylation could be investigated in mammalian cells treated with compound 7 
and/or its structural analogues in order to support the HMT inhibitory activity of the novel 
compounds.
○
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Padalino et al. used a multidisciplinary approach (functional genomics, molecular modeling 
and efficacy studies on different developmental stages of S. mansoni) for the discovery of 
novel targets and drugs for the treatment of schistosomiasis. Schistosomiasis is a neglected 
tropical parasitic disease affecting more than 200 million people in the poorest regions of 
the world. Today, the treatment and most control initiatives for schistosomiasis rely on a 
single drug, praziquantel (PZQ) that has high efficacy, few and transient side effects, 
competitive cost. However, while very active on adult parasites, PZQ is poorly effective 
against juvenile worms both in vitro and in vivo. Moreover, the constant and massive use of 
a single drug has raised concerns about the possibility of emerging drug resistance. 
Therefore, the discovery of new drug targets and compounds is required. Targeting the 
epigenome has emerged as a new strategy for the treatment of parasitic diseases including 
schistosomiasis. 
  
The present study identifies a novel potentially relevant drug target, a histone methyl 
transferase (HMT), SmMML-1 in Schistosoma mansoni. Moreover, new multi-stage active 
compounds were identified and characterized. 
  
Comment: Overall the work is well written, the study is well hypothesized, designed and 
executed. The results support the majority of the conclusions. Unfortunately, it is not clear 
at this stage whether the novel compounds are acting on the MLL-1 homologue in S. 
mansoni. I think the following suggestions could help you to address this open issue. 
 
Smp_138030 was characterized as the closest homologue of the human mixed 
lineage leukemia (MLL) HMT. Silencing of Smp_138030 (60%) resulted in motility and 
egg production defects in adult worms; however, no statistically significant change of 
H3K4 methylation was detected in knockdown parasites. This finding suggests that 
the MLL-1 homologue in S. mansoni might target different enzymatic substrates 
and/or that silencing of other HMT genes is required to impair H3K4 methylation in S. 
mansoni.
○
  
Response: Please see our response to Reviewer 2’s almost identical query. 
Bioinformatic characterisation of S. mansoni genome identified three different genes 
encoding schistosome proteins containing MLL-specific domains (Smp_138030, 
Smp_144180 and Smp_070170) (Ref: doi.org/10.1016/j.ijpddr.2018.10.005). 
The human MLL family includes five protein members, which are involved in mono-, di-, and 
trimethylation of H3K4 (Ref: doi.org/10.17554/j.issn.2313-5611.2015.01.17). However, the 
catalytic specificity of each human MLL homologue is currently unclear (Ref: 
doi.org/10.7554/eLife.01503.001). Similarly, we can’t exclude a functional redundancy in the 
histone code since the same epitope (e.g. the methylation of a specific amino acid residue) 
can be introduced by several components of the histone methylation machinery in the 
parasite. 
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Thus, it can be concluded that methylation activity in siSmp_138030 treated worms (60% 
knockdown) can be compensated for by other components of the schistosome methylation 
machinery (such as Smp_070170 and Smp_144180) leading to only a slight demethylation 
effect (9% decrease in global H3K4 methylation).  We have postulated this in our discussion. 
 We also can’t exclude that siRNA-mediated silencing of the other two members of the MLL 
family (individually or in combination with Smp_138030) would result in a stronger 
phenotype. An ongoing project is looking into this by assessing the phenotypes of worms 
treated with siRNAs directed against all three MLL homologs.  
Gene expression studies of siLuc and siSmp_138030 parasites could lead to the 
identification of a SmMLL-1-associated signature. In turn this signature could be 
compared with the one derived from compound 7 and compound 7 analogs-treated 
parasites in order to support the hypothesis that the novel compounds are targeting 
SmMLL-1;
○
    
Viability assays and phenotyping studies could be performed in siLuc and 
siSmp_138030 parasites treated with sub-lethal or lethal doses of compound 7. 
Differences in the gene-silenced compound-treated parasites could support the 
hypothesis that the novel schistosomicidal compound is targeting SmMLL-1;
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H3K4 methylation should be also investigated in parasites treated with compound 7 
and/or its structural analogues;
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and/or its structural analogues in order to support the HMT inhibitory activity of the 
novel compounds.
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This study focuses on drug discovery for schistosomiasis, a neglected tropical disease affecting 
200,000,000 people. Treatment options are limited to a single drug, which has poor activity 
against some stages of worm development. The evolution of drug resistance is highly likely, with 
no alternative compounds for treatment. The topic is of great value to human health. 
 
Recent efforts to identify new drugs for schistosomiasis have identified epigenetic targets. The 
present study identifies and characterizes a new epigenetic target, a histone methyl transferase in 
Schistosoma mansoni. Functional genomic approaches were used to validate druggability of the 
target. Molecular modeling was used to identify potential compounds binding to the protein. 
Selected compounds were purchased and tested for anti-schistosome activities. Results guided 
the selection of analogs for further studies. The paper is well written and the data is clearly 
presented. The results support the conclusions for the most part. 
 
Determination of specificity of action (Table 3) is not based on an equivalent analysis of activity in 
schistosomes and mammalian cells; different end-points were measured and a comparison is not 
useful. Worms and somula were incubated for 72 hr with compound, then phenotypic analysis was 
done. HepG2 cells were cultured for either 24 hr or 20 hr (which one?) with compound, then 
viability assessed by MTT. Since different parameters are measured it is not possible to conclude 
that the inhibitors are worm selective. 
 
Assay quantifying methylation on histone H3, lysine 4 (H3K4) was performed on adult worm 
histone protein extracts. These assays revealed that smp_138030 knockdown resulted in a not 
statistically significant change of H3K4 methylation. A 60% reduction in mRNA abundance resulted 
in no change in methylation. Was methylation status of inhibitor-treated worms assessed? This 
would show that compound anti-worm activity was through inhibition of SmMLL-1 and not off 
target effects. Evidence that the compounds function through inhibition of SmMLL-1 is lacking. 
 
How many MLL paralogues are present in schistosomes? What is their identity? If this family of 
proteins is targeted, do all need to be silenced/inhibited to see a strong phenotype? 
 
A discussion of known MLL-1 inhibitors with comparison to the new inhibitors identified would be 
useful. Why were known MLL-1 inhibitors not investigated?
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highly likely, with no alternative compounds for treatment. The topic is of great value to 
human health. 
  
Recent efforts to identify new drugs for schistosomiasis have identified epigenetic targets. 
The present study identifies and characterizes a new epigenetic target, a histone methyl 
transferase in Schistosoma mansoni. Functional genomic approaches were used to validate 
druggability of the target. Molecular modeling was used to identify potential compounds 
binding to the protein. Selected compounds were purchased and tested for anti-
schistosome activities. Results guided the selection of analogs for further studies. The paper 
is well written and the data is clearly presented. The results support the conclusions for the 
most part. 
  
Comment: Determination of specificity of action (Table 3) is not based on an equivalent 
analysis of activity in schistosomes and mammalian cells; different end-points were 
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measured and a comparison is not useful. Worms and somula were incubated for 72 hr with 
compound, then phenotypic analysis was done. HepG2 cells were cultured for either 24 hr 
or 20 hr (which one?) with compound, then viability assessed by MTT. Since different 
parameters are measured it is not possible to conclude that the inhibitors are worm 
selective. 
 
Response: Cells were incubated for 20 h with the compound prior application of MTT 
reagent. After 4 h incubation (24 h drug-cell incubation in total), the absorbance reading at 
570 nm was measured with a POLARstar Omega. The methodology has been updated 
accordingly. 
Our rationale for choosing a 24 h window for HepG2 cytotoxicity estimations is based on 
two reasons. The first reason originates from the literature (Ref: 
doi.org/10.1371/journal.pone.0177902). Here, as part of the U.S. Tox21 screening program, 
HepG2 cytotoxicity of 10K chemicals was investigated at 0, 8, 16, 24, 32, and 40 h of 
exposure in a concentration dependent fashion. The results of these screens indicated that 
maximal HepG2 cytotoxicity (measuring metabolic activity, which is how we measured 
cytotoxicity in our study) of active compounds was found before 24 hours in 91% of the 
assays. This large-scale cytotoxicity screen indicated to us that an appropriate window for 
testing this library of compounds on a uniform monolayer of HepG2 cells was 24 (O/N) h. 
We have now included this reference in the Methods section to provide further justification 
of the 24 h interval.  
The second reason relates to the nature of the biological material we are comparatively 
testing in our in vitro assays. In comparison to a monolayer of HepG2 cells, schistosomes 
(schistosomula and adult worms) are much larger, multi-cellular, multi-tissue organisms 
covered by a heptalaminate membrane. We reasoned that compound-induced anthelmintic 
activities would take longer to develop in these metazoan organisms when compared to the 
HepG2 cells. This is the rationale for quantifying anti-schistosome phenotype and motility 
metrics at 72 h.  
Above all, the point raised by the reviewer is understandable, so we agreed to remove the 
selectivity index column from Table 3 and believe this won’t affect the major findings 
reported in the manuscript. We also amended the results section related to the cytotoxicity. 
  
Comment: Assay quantifying methylation on histone H3, lysine 4 (H3K4) was performed on 
adult worm histone protein extracts. These assays revealed that smp_138030 knockdown 
resulted in a not statistically significant change of H3K4 methylation. A 60% reduction in 
mRNA abundance resulted in no change in methylation. Was methylation status of inhibitor-
treated worms assessed? This would show that compound anti-worm activity was through 
inhibition of SmMLL-1 and not off target effects. Evidence that the compounds function 
through inhibition of SmMLL-1 is lacking. 
 
Response: This comment correctly highlights how the investigation of the methylation 
status of inhibitor-treated worms could confirm the mechanism of action of these 
compounds. 
We haven’t planned this experiment because we wanted firstly to see if a greater 
knockdown of Smp_138030 would result in a more significant change of H3K4 methylation 
and secondly assess the presence of a compensatory effect caused by other members of 
the MLL family (see comment below). 
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Nevertheless, we are planning to perform this additional experiment with compound 7 
and/or one of the most active compounds presented in this study. The results will then be 
included in a new version of the manuscript. 
  
Comment: How many MLL paralogues are present in schistosomes? What is their identity? 
If this family of proteins is targeted, do all need to be silenced/inhibited to see a strong 
phenotype? 
 
Response: Bioinformatic characterisation of S. mansoni genome identified three different 
genes encoding schistosome proteins containing MLL-specific domains (Smp_138030, 
Smp_144180 and Smp_070170) (Ref: doi.org/10.1016/j.ijpddr.2018.10.005). 
The human MLL family includes five protein members, which are involved in mono-, di-, and 
trimethylation of H3K4 (Ref: doi.org/10.17554/j.issn.2313-5611.2015.01.17). However, the 
catalytic specificity of each human MLL homologue is currently unclear (Ref: 
doi.org/10.7554/eLife.01503.001). Similarly, we can’t exclude a functional redundancy in the 
histone code since the same epitope (e.g. the methylation of a specific amino acid residue) 
can be introduced by several components of the histone methylation machinery in the 
parasite. 
Thus, it can be concluded that methylation activity in siSmp_138030 treated worms (60% 
knockdown) can be compensated for by other components of the schistosome methylation 
machinery (such as Smp_070170 and Smp_144180) leading to only a slight demethylation 
effect (9% decrease in global H3K4 methylation).  We have postulated this in our discussion. 
We also can’t exclude that siRNA-mediated silencing of the other two members of the MLL 
family (individually or in combination with Smp_138030) would result in a stronger 
phenotype. An ongoing project is looking into this by assessing the phenotypes of worms 
treated with siRNAs directed against all three MLL homologs.   
   
Comment: A discussion of known MLL-1 inhibitors with comparison to the new inhibitors 
identified would be useful. Why were known MLL-1 inhibitors not investigated? 
 
Response: Pharmacological targeting of HsMLL substrate or cofactor binding pockets has 
so far been unsuccessful (Ref: doi.org/10.1002/pro.3129). The main drug discovery efforts 
around this target have focused on small molecules disrupting chromatin complexes (Ref: 
doi.org/10.1016/j.chembiol.2016.07.014 and doi.org/10.1002/pro.3129). For instance, HsMLL 
binds via its N terminus to Menin and via its C terminus to WDR5, two molecular scaffolds 
coordinating the functions of multiple proteins. 
We have investigated the activity of two commercially available chemical probes: MI-1 
(SML0537, Sigma) and OICR-9429 (kindly provided by Structure Genomics Consortium - 
https://www.thesgc.org/chemical-probes/OICR-9429). The first probe targets the MLL-
binding domain of Menin and effectively disrupts the Menin-MLL interaction (Ref: 
doi.org/10.1038/nchembio.773); the second targets the MLL-binding domain of WDR5, 
disrupting the WDR5-MLL interaction (Ref: doi.org/10.1038/nchembio.1859). 
These two compounds were screened on schistosomula at 10 µM (Figure A) and only MI-1 
was identified as hit. A subsequent titration of this compound (Figure B) didn’t show a 
strong anti-schistosomal activity (EC50 of 3.97 and 2.03 µM for phenotype and motility, 
respectively – Figure B). 
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Figure A - Mechanically-transformed schistosomula (n = 120) were incubated with the 
selected compounds (10 µM of MI-1 and OICR-9429 in 0.625% DMSO; each of them in 
duplicate) for 72 h at 37°C in a humidified atmosphere containing 5% CO2. Three 
independent screens (each including two technical replicates) were performed for each 
compound. Phenotype and motility Z´ values for each screen are summarized in the 
following table. Compounds with activity on both schistosomula phenotype and motility are 
shown within the hit zone (delineated by the dotted red lines in the graph). 
 
Figure B - Dose-response titration (10, 5, 2.5, 1.25 and 0.625 µM) of MI-1 on mechanically-
transformed schistosomula looking at both phenotype (P) and motility (M) scores. Three 
independent dose response titrations were performed, and each compound concentration 
was evaluated in duplicate. One of three replicate screens is shown here (barcode 0359). 
The dotted red line identifies the hit zone. 
 
We haven’t included these results in the manuscript because their mechanism of action is 
quite different to the putative mechanism of action of molecules described in this study.  
Therefore, their different anti-schistosomal results cannot be directly compared. 
  
We would like to thank the Reviewer and the Editorial Team very much for their detailed and 
very constructive comments, which have helped us to improve our manuscript. We hope 
that this point-by-point response could clarify the open questions and that our suggested 
revisions are clear and convincing. We are, of course, happy to discuss any further open 
issues. 
  
Kind regards, 
  
Gilda Padalino (on behalf of the authors)  
Competing Interests: No competing interests were disclosed.
Reviewer Report 23 July 2020
https://doi.org/10.21956/wellcomeopenres.17631.r39615
© 2020 Miele A. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Adriana Erica Miele   
1 Institute of Chemistry, Molecular and Supramolecular Biochemistry(ICBMS), UMR 5246 CNRS - 
UCBL, University of Lyon, Lyon, France 
2 Dept. Biochemical Sciences, Sapienza University of Rome, Rome, Italy 
The manuscript by Padalino and co-Authors presents a complete process of lead discovery, from 
target validation to virtual screening, from high content screening against different life stages of 
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Schisotoma mansoni parasites to preliminary SAR and selectivity tests to guide in lead choice and 
optimization. The results on the new scaffold, based on a piperazine ring connected to a 1,3,5-
triazine core, are indeed very promising. The optimised leads built from compound 7 represent 
good expectations in the quest for new drugs against schistosomiasis. 
 
All the data are very well explained and all the methods are clearly presented, either in the 
manuscript or in the numerous supplementary files. 
One curiosity on the bioinformatics tools/software used: it is true that many programmes 
nowadays are available to perform both homology modelling and ligand docking, but which is the 
point to give only one alternative in the manuscript? I refer to the sentence at p.4 paragraph 3 
"Modeller could be a valid alternative"; a similar sentence at p. 5 paragraphs 3 and 4 and in Figure 
1 "AutoDock could alternatively be used .." 
If Authors have used only one programme (MOE and Glide) for each purpose and for any good 
reason, why give only one alternative? There are many others out there. 
 
On the other hand, if the Authors have used both programmes (MOE and Modeller; Glide and 
AutoDock), then it could be wise to give a comparison of the results based on the two softwares. 
The rationale of the research project is clear and the manuscript reads easily, without the need to 
go back and forth to the supplementary files, unless for an in depth examination and thorough 
understanding. 
 
A few minor comments/suggestions:
In the keywords Authors might add MLL, unless there is a limit given in the journal's 
instructions; 
 
○
p. 4 column 1 line 1: there is a typo in  "ad libitum"; 
 
○
p. 4 column 1 lines 7 and 11: the buffer used is PBS. 1x does not mean anything, unless you 
give the recipe 
 
○
p. 4 column 1, paragraph 2 line 1: "double saline solution" instead of 2x saline; 
 
○
p. 4 column 1 "Homology modelling". Does 58% sequence similarity between human and 
schistosoma MLL refer to the SET domain alone? In that case, please use both PDB ID and 
chain ID (here 5F6K:C); 
 
○
p. 5 SBVS framework: why have the Authors used the OPLS_2005 force field instead of the 
newest OPLS3? 
 
○
Figure 1 panel C legend: “Same orientation as in B, but highlighting the structural motifs I to IV 
in black.” instead of “Schematic representation of Smp_138030’s domain architecture with 
indication of the different motifs (black regions on the protein represented as green 
ribbon)”. 
 
○
The yellow ribbon is “peptide form histone H3”, not “histone protein”. 
 
○
Figure 2 legend: a space is missing between “indicated.All siRNA” 
 
○
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Figure 2 vs Fig. 4,5,7: why the p-values of figure 2 are different from those of the other 
figures? Are the cut-off different? Moreover the ** value is missing in figure 2. 
 
○
Figure 4B: for clarity it would be better to present the data from 0 to 50 and then a broken y 
axis line and start again from 300 to 400, so that the tiny differences between PZQ and 
compound 7 could be highlighted. 
 
○
Figure 5 legend: were the measurements done in duplicate or in triplicate? 
 
○
Table 3: SI for compound 20 is >24, not ND 
 
○
Figure 6: the title of this figure should be the same as that of Figure 5 with the exception of 
Set 3. The present title is misleading → it cites schistosomula and then presents the egg 
counts. 
 
○
Figure 6C and 6D vs 4B and 5D: why are the DMSO egg counts at 150 (6C,D) instead of 300 
(4B,5D)? 
 
○
Figure 7: p-values are missing in the legend. 
 
○
p. 13 column 2 “Discussion”: please use “Therefore” instead of “Because of this realisation” 
 
○
p. 14 column 2 line 4: insert a “,” between “maintenance” and “including”○
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Molecular parasitology, host-parasite interactions, structural biochemistry
I confirm that I have read this submission and believe that I have an appropriate level of 
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expertise to confirm that it is of an acceptable scientific standard.
Author Response 15 Oct 2020
Gilda Padalino, Aberystwyth University, Aberystwyth, UK 
We thank the Reviewer very much for the detailed and constructive comments on our 
manuscript entitled: “Identification of 6-(piperazin-1-yl)-1,3,5-triazine as a chemical 
scaffold with broad anti-schistosomal activities”, submitted to Wellcome Open Research
.  
 
Reviewer #1 Comments: 
The manuscript by Padalino and co-Authors presents a complete process of lead discovery, 
from target validation to virtual screening, from high content screening against different life 
stages of Schisotoma mansoni parasites to preliminary SAR and selectivity tests to guide in 
lead choice and optimization. The results on the new scaffold, based on a piperazine ring 
connected to a 1,3,5-triazine core, are indeed very promising. The optimised leads built 
from compound 7 represent good expectations in the quest for new drugs against 
schistosomiasis. 
  
All the data are very well explained and all the methods are clearly presented, either in the 
manuscript or in the numerous supplementary files. 
  
Comment: One curiosity on the bioinformatics tools/software used: it is true that many 
programmes nowadays are available to perform both homology modelling and ligand 
docking, but which is the point to give only one alternative in the manuscript? I refer to the 
sentence at p.4 paragraph 3 "Modeller could be a valid alternative"; a similar sentence at p. 
5 paragraphs 3 and 4 and in Figure 1 "AutoDock could alternatively be used .." 
If Authors have used only one programme (MOE and Glide) for each purpose and for any 
good reason, why give only one alternative? There are many others out there. 
 
Response: During this study, MOE and Schrödinger (including Glide) were used for the 
homology modelling and the in silico virtual screen, respectively. However, these are licence 
managed software packages and, upon request of Wellcome Open Research’s editorial 
team, we were encouraged to suggest at least one freely available alternative that 
readers/referees could use to replicate our study. 
 
Comment: On the other hand, if the Authors have used both programmes (MOE and 
Modeller; Glide and AutoDock), then it could be wise to give a comparison of the results 
based on the two softwares. 
 
Response: As mentioned above, only one software was used for each task so we can’t 
provide a comparison of results as requested. 
  
Comment: The rationale of the research project is clear and the manuscript reads easily, 
without the need to go back and forth to the supplementary files, unless for an in depth 
examination and thorough understanding. 
 
 
Page 34 of 37
Wellcome Open Research 2020, 5:169 Last updated: 24 NOV 2020
A few minor comments/suggestions: 
  
Comment: In the keywords Authors might add MLL, unless there is a limit given in the 
journal's instructions; 
Response: The selection of the keywords was done during the submission process and we 
are not sure if this can be changed now. If so, we’ll update the list with ‘MLL’ as keyword. 
  
Comment: p. 4 column 1 line 1: there is a typo in  "ad libitum"; 
Response: We have made corrections as suggested. 
  
Comment: p. 4 column 1 lines 7 and 11: the buffer used is PBS. 1x does not mean anything, 
unless you give the recipe 
Response: Detailed description of buffer composition was included in the manuscript. 
  
Comment: p. 4 column 1, paragraph 2 line 1: "double saline solution" instead of 2x saline; 
Response: We have made corrections as suggested. 
  
Comment: p. 4 column 1 "Homology modelling". Does 58% sequence similarity between 
human and schistosoma MLL refer to the SET domain alone? In that case, please use both 
PDB ID and chain ID (here 5F6K:C); 
Response: We have made corrections as suggested. 
     
Comment: p. 5 SBVS framework: why have the Authors used the OPLS_2005 force field 
instead of the newest OPLS3? 
Response: The licence we have used only allowed us to apply the OPLS_2005 force field 
rather than the newest one. 
  
Comment: Figure 1 panel C legend: “Same orientation as in B, but highlighting the 
structural motifs I to IV in black.” instead of “Schematic representation of Smp_138030’s 
domain architecture with indication of the different motifs (black regions on the protein 
represented as green ribbon)”. 
Response: We have made corrections as suggested. 
  
Comment: The yellow ribbon is “peptide form histone H3”, not “histone protein”. 
Response: We replaced the expression “histone protein” with “peptide from histone H3” as 
a more appropriate description. 
     
Comment: Figure 2 legend: a space is missing between “indicated.All siRNA” 
Response: This is probably a layout-related issue. A space is correctly present in the 
manuscript. 
     
Comment: Figure 2 vs Fig. 4,5,7: why the p-values of figure 2 are different from those of the 
other figures? Are the cut-off different? Moreover the ** value is missing in figure 2. 
 
Response: The p values illustrated in Figure 2 are derived from the Student’s two tailed t 
test, unequal variance - Mann-Whitney U-test. On the other hand, a different test was used 
for the data presented in Figure 4, 5 and 7.  Here, a Kruskal-Wallis ANOVA followed by 
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Dunn’s multiple comparisons test was used; hence, the statistical significance values are 
differently presented. 
 ** value was included in the updated version of the manuscript. 
     
Comment: Figure 4B: for clarity it would be better to present the data from 0 to 50 and then 
a broken y axis line and start again from 300 to 400, so that the tiny differences between 
PZQ and compound 7 could be highlighted. 
 
Response: This is a good suggestion, however, there was complete inhibition of egg 
production after treatment with compound 7 (all concentrations tested except for 6.25 uM) 
and no eggs were recovered from the positive control (PZQ). 
     
Comment: Figure 5 legend: were the measurements done in duplicate or in triplicate? 
Response: As indicated in the Figure legend, Panel A and Panel B measurements were 
performed in duplicate.  Measurements in Panels C and D were conducted in duplicate 
during two independent screens (4 measurements in total). 
     
Comment: Table 3: SI for compound 20 is >24, not ND 
Response: Based on Reviewer#2’s comments, we have decided to remove the SI column 
from Table 3. 
     
Comment: Figure 6: the title of this figure should be the same as that of Figure 5 with the 
exception of Set 3. The present title is misleading → it cites schistosomula and then presents 
the egg counts. 
Response: This is a good suggestion. We have updated the title using the expression “Anti-
schistosomal activity”, which should cover all the different results presented in the figure 
and to avoid repeating the same title of Figure 5. 
     
Comment: Figure 6C and 6D vs 4B and 5D: why are the DMSO egg counts at 150 (6C,D) 
instead of 300 (4B,5D)? 
Response: The egg count data for the negative control DMSO is different because the 
number of worm pairs used for the experiment was different. For Figures 4 and 5, three 
worm pairs were used for each condition, so the egg counts in the DMSO control are in the 
range of 300 eggs. For Figure 6, only one pair worm was used so the DMSO control has 
fewer eggs (~150). Figure 4, 5 and 6 legends were updated accordingly. The methodology 
was updated as well. 
     
Comment: Figure 7: p-values are missing in the legend. 
Response: To avoid repetition, we refer to Figure 4 for the statistical analysis information as 
the same approach was used (Kruskal-Wallis ANOVA followed by Dunn’s multiple 
comparisons test) and the p-values are as indicated in Figure 4’s legend. However, as 
suggested, the figure legend was updated to incorporate the specific p values accordingly. 
     
Comment: p. 13 column 2 “Discussion”: please use “Therefore” instead of “Because of this 
realisation” 
Response: We have made corrections as suggested 
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Comment: p. 14 column 2 line 4: insert a “,” between “maintenance” and “including” 
Response: We have made corrections as suggested  
 
We would like to thank the Reviewer and the Editorial Team very much for their detailed and 
very constructive comments, which have helped us to improve our manuscript. We hope 
that this point-by-point response could clarify the open questions and that our suggested 
revisions are clear and convincing. We are, of course, happy to discuss any further open 
issues. 
  
Kind regards, 
  
Gilda Padalino (on behalf of the authors)  
Competing Interests: No competing interests were disclosed.
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